Biogen (BIIB) Stock Upgrade: Target Raised to $225 from UBS
Published on Β· Source: investing.com
AI Summary
Summarized by AI from the source belowUBS has upgraded Biogen (BIIB) stock, citing favorable pipeline catalysts as a key reason. The target price for Biogen shares has been raised to $225. This adjustment reflects confidence in the company's growth potential and anticipated drug approvals. The upgrade may positively influence market perception and investor interest in Biogen moving forward.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Biogen Inc. (BIIB)
Biogen is a biotech focused on neurological diseases.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier BIIB news
- Apellis (APLS) Stock Rating Downgraded After Biogen Acquisition
- Biogen (BIIB) to Acquire Apellis for $5.6 Billion
- Apellis (APLS) Stock Rating Cut by Cantor Fitzgerald Post-Biogen Deal
- Biogen Reports Positive Phase 2 Results for Lupus Drug: Potential Market Impact
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
